Robable 2 probable 1 doable 3 probable No information 7 probable 7 attainable 1 probable

October 8, 2022

Robable 2 probable 1 doable 3 probable No information 7 probable 7 attainable 1 probable 2 doable No
Robable two probable 1 achievable three probable No information 7 probable 7 attainable 1 probable 2 feasible No information 236 probable 79 probable CAPA (White et al.) 10 putative two NC 1 NC 2 putative 1 NC three NC No data four putative ten NC two putative No data 180 putative EORTC (Donnelly et al.) 10 NC two NC 1 NC two NC 3 NC two probable 14 NC 3 NC No data 16 probable 9 possibleAuthorReizine et al. Oliva et al. Campochiaro et al. Wasylyshyn et al. NebredaMoyoral et al. Signorini et al. Rabagliati et al. Lamoth et al. Yang et al. Total2-Bromo-6-nitrophenol supplier Abbreviations. NS, not specified; NC, not classifiable.J. Fungi 2021, 7,12 ofTable 4. Case reports and case series describing candidemia related to COVID-19. Traits Candidemia circumstances Sex Median age (IQR) No. 41 Male: 32 (78) 64 (542) Diabetes mellitus: 27 (65.9) Polmacoxib Technical Information Arterial hypertension: 24 (58.5) Cardiovascular disease: 9 (21.9) Obesity: 9 (21.9) Chronic pulmonary disease: four (9.8) Steroids: 27 (65.9) Tocilizumab: eight (19.7) Baricitinib: 7 (17.1) 13.5 (7.59.five) 35 (85.four) 5 (12.8) 34 (82.9) 36 (87.8) C. albicans: 18 (40.9) C. auris: 11 (26.eight) C. glabrata: six (14.six) C. tropicalis: four (9.eight) Other: five (12.2) Total: 44 Retinitis: 1 Endocarditis: 1 Endophathalmitis: 1 Osteomyelitis: 1 36 (87.eight) Anidulafungin: 16 (44.4) Caspofungin: 13 (36.1) Fluconazole: 12 (33.three) Other azoles: 5 (13.9) AMB: four (11.1) Other: three (eight.three) 23 (56.1)Main underlying diseasesCOVID-19 treatment options Median number of days from ICU admission or TI to candidemia (IQR) No. of sufferers with central venous catheters No. of sufferers on total parenteral nutrition No. of sufferers on antibiotic therapy No. of patients undergoing mechanical ventilationCandida speciesNo. of sufferers using a secondary focusNo. sufferers receiving anti-fungal remedy Anti-fungal agentsNumber of deathsData are absolute numbers (percentages) unless otherwise specified. Abbreviations: ICU, intensive care unit; IQR, interquartile variety; TI, tracheal intubation; AMB, amphotericin B.Table five. Observational studies reporting candidemia linked to COVID-19. Characteristics No. of candidemia cases/total quantity of sufferers Sex No. 360/9451 (3.eight) Male: 162 (45.1) Diabetes mellitus: 91 (25.three) Arterial hypertension: 74 (20.six) Cardiovascular disease: 60 (16.7) Chronic pulmonary illness: 37 (ten.three) Obesity: 23 (6.four) Steroids: 156 (43.4) Tocilizumab: 69 (19.two) 247/267 (92.5) 49/229 (21.4) 172/180 (95.6) 227/271 (83.eight)Major underlying diseasesCOVID-19 therapies No. of individuals with central venous catheters No. of individuals on total parenteral nutrition No. of individuals on antibiotic therapy No. of sufferers undergoing mechanical ventilationJ. Fungi 2021, 7,13 ofTable five. Cont. Characteristics No. C. albicans: 164 (44.four) C. glabrata: 51 (14) C. parapsilosis: 50 (13.eight) C. tropicalis: 31 (8.five) C. auris: 20 (five.5) C. dubliniensis: four (1.1) Other: 43 (11.8) Total: 363 190/253 (75) Fluconazole: 38 (20) Anidulafungin: 37 (19.4) Caspofungin: 25 (13.2) Micafungin: 20 (10.five) Fluconazole: 38 (20) Other azoles: five (two.6) 202/270 (74.eight)Candida speciesNo. of sufferers receiving anti-fungal treatment Anti-fungal agentsNo. of deathsData are absolute numbers (percentage), unless otherwise specified. Abbreviations: ICU, intensive care unit; IQR, interquartile range; TI, tracheal intubation; AMB, amphotericin B.three.3. Mucormycosis The literature search identified 45 articles reporting situations of COVID-19-associated mucormycosis [18,45,61,84,88,13877]. A lot of the articles were from India (19, 42 ) plus the USA (9, 20 ); eight articles were from Europ.